儿童期诊断的肥厚型心肌病长期结局:全国人群研究
澳大利亚儿童心肌病研究纳入1987至1996年诊断的80例肥厚型心肌病患儿(诊断中位年龄0.48岁),1年、10年、20年无死亡/移植生存率分别为86%、80%、78%。诊断时对称性左室肥厚、Noonan综合征、较高后壁厚度z评分及随访中较低缩短分数z评分与死亡/移植风险独立相关。
要点
- 儿童肥厚型心肌病死亡或移植风险最高在诊断后1年内,此后较低。
- 诊断时对称性左室肥厚和Noonan综合征是独立风险因素。
- 随访中较高后壁厚度z评分和较低缩短分数z评分与不良结局相关。
核心结论
- 儿童肥厚型心肌病诊断后1年内死亡或移植风险最高,此后风险较低。
研究设计与样本
- 澳大利亚儿童心肌病研究为纵向人群队列,纳入1987至1996年诊断的0-10岁心肌病患儿,其中肥厚型心肌病80例,诊断中位年龄0.48岁(四分位距0.1-2.5岁)。
主要发现
- 无死亡/移植生存率1年为86%(95%CI 77.0-92.0),10年为80%(95%CI 69.0-87.0),20年为78%(95%CI 67.0-86.0)。
- 多变量分析显示,诊断时对称性左室肥厚(HR 4.20,95%CI 1.60-11.05,P=0.004)和Noonan综合征(HR 2.88,95%CI 1.02-8.08,P=0.045)与死亡/移植风险独立相关。
- 随访中较高后壁厚度z评分(HR 1.45,95%CI 1.22-1.73,P<0.001)和较低缩短分数z评分(HR 0.84,95%CI 0.74-0.95,P=0.005)也与死亡/移植风险相关。
- 19例(23%)接受左室心肌切除术;中位随访15.7年时,63例存活者中27例(42%)使用β受体阻滞剂,13例(21%)植入ICD。
临床怎么用
- 儿童肥厚型心肌病诊断后第一年应密切监测,关注死亡或移植风险。
- 诊断时对称性左室肥厚或合并Noonan综合征的患儿需加强风险评估。
- 随访中后壁厚度z评分升高和缩短分数z评分降低提示不良预后,应优化管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Late survival and symptomatic status of children with hypertrophic cardiomyopathy have not been well defined. We examined long-term outcomes for pediatric hypertrophic cardiomyopathy. METHODS: The National Australian Childhood Cardiomyopathy Study is a longitudinal population-based cohort study of children (0-10 years of age) diagnosed with cardiomyopathy between 1987 and 1996. The primary study end point was time to death or cardiac transplantation. RESULTS: There were 80 patients with hypertrophic cardiomyopathy, with a median age at diagnosis of 0.48 (interquartile range, 0.1, 2.5) years. Freedom from death/transplantation was 86% (95% confidence interval [CI], 77.0-92.0) 1 year after presentation, 80% (95% CI, 69.0-87.0) at 10 years, and 78% (95% CI, 67.0-86.0) at 20 years. From multivariable analyses, risk factors for death/transplantation included symmetrical left ventricular hypertrophy at the time of diagnosis (hazard ratio, 4.20; 95% CI, 1.60-11.05; P=0.004), Noonan syndrome (hazard ratio, 2.88; 95% CI, 1.02-8.08; P=0.045), higher posterior wall thickness z score (hazard ratio, 1.45; 95% CI, 1.22-1.73; P<0.001), and lower fractional shortening z score (hazard ratio, 0.84; 95% CI, 0.74-0.95; P=0.005) during follow-up. Nineteen (23%) subjects underwent left ventricular myectomy. At a median of 15.7 years of follow-up, 27 (42%) of 63 survivors were treated with β-blocker, and 13 (21%) had an implantable cardioverter-defibrillator. CONCLUSIONS: The highest risk of death or transplantation for children with hypertrophic cardiomyopathy is within 1 year after diagnosis, with low attrition rates thereafter. Many subjects receive medical, surgical, or device therapy.
引用
- Alexander PMA, Nugent AW, Daubeney PEF, et al. Long-Term Outcomes of Hypertrophic Cardiomyopathy Diagnosed During Childhood: Results From a National Population-Based Study. Circulation. 2018. PMID: 29490994. doi:10.1161/CIRCULATIONAHA.117.028895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。